Avanti® Polar Lipids MPLA (PHAD®)

Merck KGaA, Darmstadt, Germany699800PAvailable: ,Western Europe,Asia,Eastern Europe,South Central America,Caribbean,Australia Oceania,Middle East,Africa,Other

Monophosphoryl Lipid A (Synthetic) (PHAD®), powder

Merck KGaA, Darmstadt, Germany

The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our  Product Directory.

Ease of Use
After Sales Service
Value for Money
Be the first to leave a review

Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD®), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.

Packaging

  • 2 mL Amber Glass Crimp Cap Vial (699800P-1mg)
  • 2 mL Amber Glass Crimp Cap Vial (699800P-5mg)

Other Notes

  • For R&D use only. Not for drug, household, or other uses.

Product Overview

Links